Результаты поиска

Expert consensus on resection of chest wall tumors and chest wall reconstruction.

Chest wall tumors are a relatively uncommon disease in clinical practice. Most of the published studies about chest wall tumors are usually single-center retrospective studies, involving few patients. Therefore, evidences regarding clinical conclusions about chest wall tumors are lacking, and some controversial issues have still to be agreed upon. In January 2019, 73 experts in thoracic surgery, plastic surgery, science, and engineering jointly released the Chinese Expert Consensus on Chest Wall Tumor Resection and Chest Wall Reconstruction (2018 edition). After that, numerous experts put forw

Fingolimod и риск заболевания раком кожи у лиц с множественным склерозом: протокол когортного исследования на основе популяции.

ВВЕДЕНИЕ: Для изучения последствий рака кожи у лиц с множественным склерозом (MS), обработанных финголимодом, необходимы долгосрочные исследования по вопросам безопасности населения с применением передовых методов установления причинно-следственных связей, в том числе с активным компаратором с дизайном новых пользователей. Цель этого исследования состоит в том, чтобы охарактеризовать протокол изучения взаимосвязи между использованием финголимодов и заболеваемостью раком кожи у лиц с НР. МЕТОДЫ И АНАЛИЗ: Мы будем использовать данные об административном здоровье населения из двух канадских прови

Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas.

BackgroundCarbapenem-resistant Enterobacterales (CRE) pose a significant global public health threat. Resistance among CRE is particularly complex, owing to numerous possible resistance mechanisms and broad definitions. We aimed to characterize the clinical and molecular profiles of CRE in the South Texas region.Materials and methodsWe compared the clinical, genotypic, and phenotypic profiles of carbapenemase producing Enterobacterales (CPE) with those of non-carbapenemase producers (NCPE) isolated from South Texas, United States between 2011 and 2019. Molecular characteristics and resistance

Histone deacetylase 6: A new player in oxidative stress‑associated disorders and cancers (Review).

Histone deacetylase 6 (HDAC6), a distinctive member of the histone deacetylase family, plays a crucial role in regulating the cellular response to oxidative stress. Unlike other HDACs, HDAC6 primarily deacetylates non‑histone proteins, influencing various cellular functions critical to the pathogenesis of numerous oxidative stress‑related diseases. This review summarizes the latest research on how HDAC6 affects oxidative stress pathways and its impact on diseases such as neurodegeneration, cancer and cardiovascular disorders. Additionally, the therapeutic potential of targeting HDAC6, as evide

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.

AbstractPeer support has been associated with improved patient-reported outcomes (PROs), including reduced psychological distress, among patients undergoing hematopoietic stem cell transplantation (HSCT), but structured interventions are limited. This study assessed the feasibility, acceptability, and preliminary effects of a scalable peer support intervention to reduce psychological distress and enhance quality of life (QOL) post-HSCT. We conducted a pilot randomized clinical trial evaluating the Supporting Transplant Experiences with Peer Program (STEPP), a 5-session, telephone-based interve

Candidate Regulatory Relationship and Expression Correlation Between miR-33a-5p and ANK3 in Chronic Myeloid Leukemia.

Chronic myeloid leukemia (CML) is a type of bone marrow cancer characterized by the uncontrolled proliferation of myeloid cells. MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in the post-transcriptional regulation of gene expression. This study aims to examine the association between miR-33a-5p and Ankyrin 3 (ANK3) in CML and to investigate the regulatory mechanisms of miR-33a-5p in the progression of this disease. mRNA expression profiles were obtained from the GSE100026 dataset within the Gene Expression Omnibus (GEO) repository. Quantitative real-time polym

A Comprehensive Review of the Diagnosis and Management of Acute Liver Failure.

Acute liver failure (ALF) is a rare and specific form of severe hepatic dysfunction characterized by coagulopathy and hepatic encephalopathy in a patient with no known liver disease. ALF carries a high morbidity and mortality. Careful attention should be given to hemodynamics and metabolic parameters along with the active surveillance of infections. Timely transfer and supportive management are important in an intensive care unit in a liver transplant center. Identifying patients who will and will not improve with medical management and may need emergent liver transplantation is critical. In t

Повторная оценка биопсии почек в связи с диабетической болезнью почек: гистопатология, курс клинической медицины и будущее точной нефрологии.

Фон: диабетическое заболевание почек (DKD) one :: основные причины хронических заболеваний и почечной недостаточности во всем мире. Хотя большинство пациентов, страдающих диабетом, диагностируются клинически на основе албуминурии, предполагаемого снижения уровня глумерной фильтрации и диабетической ретинопатии, одни только клинические параметры не могут надежно отличать биопсию, подтвержденную диабетической нефропатией (ННН), от недиабетической болезни почек (НДКД) или смешанных повреждений. Таким образом, биопсия почек для больных диабетом по-прежнему носит избирательный, а не рутинный характ

Оценка риска и прогнозирование самоубийств у нескольких пациентов с миэломой.

ЦЕЛЬ: Несмотря на успехи в лечении, позволившие выжить, множество миеломы (ММ) по-прежнему является тревожным диагнозом со значительными последствиями для здоровья, включая повышенный риск самоубийства. Целью этого исследования является изучение риска самоубийств среди пациентов с ОМ и разработка модели прогнозирования для выявления лиц с высокой степенью риска. Методы: Мы проанализировали 83,333 Случаи MM из последней базы данных наблюдения, эпидемиологии и конечных результатов (SEER)2001-2020) для выявления предсказателей риска самоубийства и разработки предсказуемых номограмм. Эта группа бы

Клинические характеристики и прогнозный анализ three hundred и nineteen - случаи первичного желудочно-кишечного диффузного большого лимфомы B-клеток.

С января были ретроспективно проанализированы клинические данные пациентов, диагностированных с помощью ПГИ-ДЛБКЛ в больнице, аффилированной с Ксинцзянским медицинским университетом. 2010 по апрель 2022A. Общее число 319 Пациенты с PGI-DLBCL были включены и разделены на тренировки (n = 223) и подтверждение (n = 96) группы. Средний возраст жителей составил 55 лет, с 48.9% мужчины и мужчины 51.1% Женщины-больные. К числу ключевых клинических особенностей относится положение дел с деятельностью Восточнокооперативной онкологической группы ≥ 2 (В тыс.40.8%), продвинутое заболевание (этап IV: 27.6%)

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania.

PurposeThe primary objective of this study was to evaluate the compliance of Romanian physicians with the national therapeutic protocol and international guidelines on treatment with erythropoiesis-stimulating agents in anemic cancer patients receiving chemotherapy. The secondary objective was to assess the hemoglobin (Hb) level change due to anemia treatment and safety of darbepoetin alfa.MethodsThis was a single-arm, prospective, longitudinal, multicenter, observational study in patients with nonmyeloid malignancies and symptomatic chemotherapy-induced anemia treated concomitantly with darbe

Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.

Chimeric antigen receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory B-cell malignancies. Despite therapeutic success, infectious complications remain a major contributor to non-relapsed morbidity and mortality. The risk of infection reflects a prolonged and multifactorial state of immunosuppression resulting from lymphodepleting chemotherapy, treatment-related cytopenia, sustained CD4+ T-cell lymphopenia, B-cell aplasia with hypogammaglobulinemia, and the use of corticosteroids or cytokine-directed therapies for the management of immune effector cell-associate

Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024.

The rising global cancer burden underscores the urgent need for innovative and effective therapies. Molecular and cellular immunology advances have revolutionized cancer immunotherapy, transforming laboratory discoveries into clinical breakthroughs. The Second Bone Marrow Transplant and Cellular Therapy Congress, held in Abu Dhabi, United Arab Emirates (UAE), on October 26th - 27th, 2024, and sponsored by the Abu Dhabi Stem Cells Center (ADSCC), convened global experts to discuss cutting-edge developments in adoptive cell transfer (ACT); chimeric antigen receptor T-cell (CAR-T) therapy, tumor-

Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.

Treatment for relapsed acute lymphoblastic leukemia (ALL) in children and young adults continues to evolve. Despite optimization of cytotoxic chemotherapeutic approaches and risk-adapted therapy, about 12% of pediatric patients still relapse, and survival rates in this population remain poor. Salvage therapy for relapsed patients continues to be challenging as attempts to further intensify chemotherapy have resulted in excessive toxicity without improving outcomes. Immunotherapy has profoundly impacted the landscape of relapsed ALL by harnessing the patient's immune system to target and elimin

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.

IntroductionTraditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.MethodBy reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of

Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.

Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have been reported. Mechanistically, can be divided into two categories: (1) toxicities related to T-cell activation and release of high levels of cytokines: or (2) toxicities resulting from interaction between CAR and CAR targeted antigen expressed on non-malignant cells (i.e., on-target, off-tumor effec

Совпадение в полном тексте источника
… Toxicities and Overall Outcomes—Real World Data Explored As compared to the patients in the pivotal trials, patients in the real-world studies were significantly older, with worse functional status and higher rates of bridge therapy [ 79 ]. … Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 2022;19:342–355. doi: 10.1038/s41571-022-00607-3. 80. Westin J.R., Kersten M.J., Salles G., Abramson J.S., Schuster S.J., Locke F.L., Andreadis C. …

Application of Next Generation Sequencing in Laboratory Medicine.

The rapid development of next-generation sequencing (NGS) technology, including advances in sequencing chemistry, sequencing technologies, bioinformatics, and data interpretation, has facilitated its wide clinical application in precision medicine. This review describes current sequencing technologies, including short- and long-read sequencing technologies, and highlights the clinical application of NGS in inherited diseases, oncology, and infectious diseases. We review NGS approaches and clinical diagnosis for constitutional disorders; summarize the application of U.S. Food and Drug Administr

Bispecific antibody targets and therapies in multiple myeloma.

Recently, several bispecific antibodies (BsAbs) have been approved for the treatment of relapsed multiple myeloma (MM) after early phase trials in heavily pre-treated patients demonstrated high response rates and impressive progression-free survival with monotherapy. These BsAbs provide crucial treatment options for relapsed patients and challenging decisions for clinicians. Evidence on the optimal patient population, treatment sequence, and duration of these therapeutics is unknown and subject to active investigation. While rates of cytokine release syndrome and neurotoxicity appear to be low

Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study.

Multiple myeloma (MM) is a common hematologic malignancy, but due to its incurable nature, patients experience many relapses in their lifetime and hence face unique challenges. This mixed-methods study consisting of an online survey and subsequent focus groups aimed to understand how social and identity experiences affected the diagnostic, treatment, and care journey for patients with MM. Twenty-three adult patients with MM participated in this study. The survey participants identified common determinants negatively impacting their health, including mental health concerns (experienced by 90.5%

Advancing Medulloblastoma Treatment: Molecular Mechanisms, Drug Repurposing, and Precision Therapies.

Medulloblastomas are the most common malignant pediatric brain tumors, representing approximately 20% of the central nervous system cancers in children. These tumors are highly heterogeneous and classified into four molecular subgroups-WNT, SHH, Group 3, and Group 4-each with distinct genetic and epigenetic profiles that influence tumor behavior, therapeutic response, and patient outcomes. Advances in molecular diagnostics have improved the subclassification of medulloblastomas, yet treatment outcomes for high-risk subtypes, particularly Group 3, remain poor, with current modalities often asso